IP Library Granted Patent US 8,071,611
Granted Patent B2
US 8,071,611 · App. 12/718,439 · Granted Dec 6, 2011

Spirocyclic heterocyclic derivatives and methods of their use

View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 8,071,611
App. No.
12/718,439
Granted
Dec 6, 2011
Kind
B2
Abstract

Spirocyclic heterocyclic derivatives, pharmaceutical compositions containing these compounds, and methods for their pharmaceutical use are disclosed. In certain embodiments, the spirocyclic heterocyclic derivatives are ligands of the δ opioid receptor and may be useful, inter alia, for treating and/or preventing pain, anxiety, gastrointestinal disorders, and other δ opioid receptor-mediated conditions.

Claims (20)

1. A method for inhibiting or treating a mood disorder selected from the group consisting of depression and bipolar manic-depression comprising administering to a patient in need thereof an effective amount of a compound of the following formula:

or a pharmaceutically acceptable salt or N-oxide thereof.

2. A method according to claim 1 wherein the mood disorder is depression.

3. A method according to claim 1 wherein the mood disorder is bipolar manic-depression.

4. A method according to claim 1 wherein said compound is in the form of a pharmaceutically acceptable salt.

5. A method according to claim 4 wherein said salt is a hydrochloride salt.

6. A method for inhibiting or treating a mood disorder selected from the group consisting of depression and bipolar manic-depression comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising, in combination with a pharmaceutically acceptable carrier, a compound of the following formula:

or a pharmaceutically acceptable salt or N-oxide thereof.

7. A method according to claim 6 wherein the mood disorder is depression.

8. A method according to claim 6 wherein the mood disorder is bipolar manic-depression.

9. A method according to claim 6 wherein said compound is in the form of a pharmaceutically acceptable salt.

10. A method according to claim 9 wherein said salt is a hydrochloride salt.

11. A method for inhibiting or treating anxiety comprising administering to a patient in need thereof an effective amount of a compound of the following formula:

or a pharmaceutically acceptable salt or N-oxide thereof.

12. A method according to claim 11 wherein said compound is in the form of a pharmaceutically acceptable salt.

13. A method according to claim 12 wherein said salt is a hydrochloride salt.

14. A method for inhibiting or treating anxiety comprising administering to a patient in need thereof an effective amount of a pharmaceutical composition comprising, in combination with a pharmaceutically acceptable carrier, a compound of the following formula:

or a pharmaceutically acceptable salt or N-oxide thereof.

15. A method according to claim 14 wherein said compound is in the form of a pharmaceutically acceptable salt.

16. A method according to claim 15 wherein said salt is a hydrochloride salt.

Assignments (3)
RELEASE OF SECURITY INTEREST Recorded Jul 24, 2015
From: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
To: CALIXA THERAPEUTICS, INC.; ADOLOR CORPORATION; CUBIST PHARMACEUTICALS, INC.
Reel/Frame 036180/0070 →
SECURITY AGREEMENT Recorded Nov 20, 2012
From: CUBIST PHARMACEUTICALS, INC.; ADOLOR CORPORATION; CALIXA THERAPEUTICS, INC.; CUBIST PHARMACEUTICALS HOLDINGS, INC.; CUBIST PHARMACEUTICALS U.S.
To: ROYAL BANK OF CANADA, AS ADMINISTRATIVE AGENT
Reel/Frame 029339/0669 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded Mar 18, 2010
From: DOLLE, ROLAND E.; LEBOURDONNEC, BERTRAND
To: ADOLOR CORPORATION
Reel/Frame 024099/0247 →